Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165 PHASE1 COMPLETED

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE1
Status	COMPLETED
Enrolment	120
Start date	Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer
• Lung Cancer
• Hepatocellular Cancer
• Colorectal Cancer
• Pancreatic Cancer
• Renal Cancer

Interventions

• NIS793
• PDR001

Countries

Hong Kong, Italy, Japan, Austria, Taiwan, Germany, Canada, Switzerland, United States